Imataki Osamu, Nakatani Shigetoshi, Hasegawa Terumi, Kondo Miki, Ichihashi Kiyoko, Araki Mitsuko, Ishida Toshihiko, Kim Sung-Won, Mori Shin-ichiro, Fukuda Takahiro, Tobinai Kensei, Tanosaki Ryuji, Makimoto Atsushi, Takaue Yoichi
Division of Hematopoietic Stem Cell Transplantation and Hematology, National Cancer Center Hospital, Tokyo, Japan.
Am J Hematol. 2006 Oct;81(10):747-52. doi: 10.1002/ajh.20700.
Patients who exhibit gastrointestinal (GI) involvement due to graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (SCT) are often recommended to withhold oral intake (NPO) to avoid further damage to the GI mucosa. However, it is possible that continuing oral intake could be beneficial in many patients compared to total parenteral nutrition (TPN).
The primary objective of this prospective study was to evaluate whether programmed step-ladder oral dieting (enteral nutrition; EN) is feasible and beneficial for these patients.
A total of 18 patients who exhibited GI-acute GVHD (stage I to III gut GVHD) after SCT received an EN dieting program, and changes in clinical and laboratory parameters were compared to those in a control cohort of 17 patients who were placed on NPO with TPN. Patients with GVHD were included prospectively and those with intestinal bleeding/obstruction, severe pancreatitis, and cytomegalovirus enterocolitis were excluded.
None of the patients in the EN group experienced significant adverse events, including exacerbation of GI symptoms. Although there was no statistically significant difference in the volume or frequency of diarrhea or the time to complete dietary recovery, parameters including body weight and serum levels of total protein and albumin tended to improve faster in the EN group.
The EN diet is safely applicable to patients suffering from GI involvement by GVHD.
异基因造血干细胞移植(SCT)后因移植物抗宿主病(GVHD)出现胃肠道(GI)受累的患者,通常建议禁食(NPO)以避免对胃肠道黏膜造成进一步损伤。然而,与全胃肠外营养(TPN)相比,许多患者继续经口摄入可能有益。
这项前瞻性研究的主要目的是评估程序化阶梯式经口饮食(肠内营养;EN)对这些患者是否可行且有益。
共有18例SCT后出现胃肠道急性GVHD(肠道GVHD I至III期)的患者接受了EN饮食方案,并将其临床和实验室参数的变化与17例接受禁食加TPN的对照队列患者进行比较。前瞻性纳入GVHD患者,排除肠道出血/梗阻、重症胰腺炎和巨细胞病毒性肠炎患者。
EN组患者均未发生包括胃肠道症状加重在内的显著不良事件。虽然腹泻量或频率以及饮食完全恢复时间无统计学显著差异,但EN组患者的体重、血清总蛋白和白蛋白水平等参数改善趋势更快。
EN饮食可安全应用于GVHD累及胃肠道的患者。